Vertex Says U.S. Places Partial Hold on Hepatitis Study

Vertex Pharmaceuticals Inc. said U.S. regulators placed a partial clinical hold on its trial of a drug for hepatitis C after three patients receiving a high dose of the medicine showed signs of potential liver toxicity. The shares sank the most in eight months.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.